These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32223373)

  • 1. A placebo prognostic index (PI) as a moderator of outcomes in the treatment of adolescent depression: Could it inform risk-stratification in treatment with cognitive-behavioral therapy, fluoxetine, or their combination?
    Lorenzo-Luaces L; Rodriguez-Quintana N; Riley TN; Weisz JR
    Psychother Res; 2021 Jan; 31(1):5-18. PubMed ID: 32223373
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
    Scott K; Lewis CC; Marti CN
    J Am Acad Child Adolesc Psychiatry; 2019 Mar; 58(3):319-328. PubMed ID: 30768414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
    March J; Silva S; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1393-403. PubMed ID: 17135984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
    Kratochvil CJ; May DE; Silva SG; Madaan V; Puumala SE; Curry JF; Walkup J; Kepley H; Vitiello B; March JS
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):519-27. PubMed ID: 19877976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating patient-specific treatment advantages in the 'Treatment for Adolescents with Depression Study'.
    Foster S; Mohler-Kuo M; Tay L; Hothorn T; Seibold H
    J Psychiatr Res; 2019 May; 112():61-70. PubMed ID: 30856378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
    Vitiello B; Rohde P; Silva S; Wells K; Casat C; Waslick B; Simons A; Reinecke M; Weller E; Kratochvil C; Walkup J; Pathak S; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1419-26. PubMed ID: 17135987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic index (PI) as a moderator of outcomes in the treatment of depression: A proof of concept combining multiple variables to inform risk-stratified stepped care models.
    Lorenzo-Luaces L; DeRubeis RJ; van Straten A; Tiemens B
    J Affect Disord; 2017 Apr; 213():78-85. PubMed ID: 28199892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
    Riggs PD; Mikulich-Gilbertson SK; Davies RD; Lohman M; Klein C; Stover SK
    Arch Pediatr Adolesc Med; 2007 Nov; 161(11):1026-34. PubMed ID: 17984403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
    O'Dor SL; Washburn J; Howard KR; Reinecke MA
    Res Child Adolesc Psychopathol; 2021 Nov; 49(11):1489-1501. PubMed ID: 34050856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
    Lewis CC; Simons AD; Nguyen LJ; Murakami JL; Reid MW; Silva SG; March JS
    J Am Acad Child Adolesc Psychiatry; 2010 Feb; 49(2):132-40. PubMed ID: 20215935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder.
    Grilo CM; Masheb RM; Crosby RD
    J Consult Clin Psychol; 2012 Oct; 80(5):897-906. PubMed ID: 22289130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double trouble: Do symptom severity and duration interact to predicting treatment outcomes in adolescent depression?
    Lorenzo-Luaces L; Rodriguez-Quintana N; Bailey AJ
    Behav Res Ther; 2020 Aug; 131():103637. PubMed ID: 32413595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.